LEXICON PHARMACEUTICALS, INC. Stock Issued During Period, Shares, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, shares, new issues for the quarter ending 2021-09-30 was 4.18M shares, a 55.24% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, shares, new issues for the quarter ending 2021-06-30 was 88.00K shares, a 52.94% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, shares, new issues for the quarter ending 2020-09-30 was 9.33M shares.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, shares, new issues for the quarter ending 2020-06-30 was 187.00K shares.
| Period end | Stock Issued During Period, Shares, New Issues 3 month | Stock Issued During Period, Shares, New Issues 12 month |
|---|---|---|
| 2021-09-30 | 4.18M shares 10-Q · filed 2021-11-09 | |
| 2021-06-30 | 88.00K shares 10-Q · filed 2021-11-09 | |
| 2020-09-30 | 9.33M shares 10-Q · filed 2020-10-30 | |
| 2020-06-30 | 187.00K shares 10-Q · filed 2020-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |